Checkpoint Therapeutics Q3 2024 Earnings Report
Key Takeaways
Checkpoint Therapeutics reported financial results for the third quarter ended September 30, 2024. The company awaits the FDA decision on its BLA resubmission for cosibelimab with a PDUFA goal date set for next month. $9.2 million in cash proceeds received from the exercise of existing warrants has strengthened the balance sheet to extend beyond the PDUFA date and into 2025.
Awaiting FDA decision on Biologics License Application (BLA) resubmission for cosibelimab.
PDUFA goal date is set for December 28, 2024.
Received $9.2 million in cash proceeds from the exercise of existing warrants.
Focusing on preparing for the potential approval of cosibelimab.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The company is preparing for the potential approval of cosibelimab and looks forward to potentially offering oncologists a new, differentiated treatment option for patients with advanced cutaneous squamous cell carcinoma.